Valuation: Byotrol Limited

Market Cap 194K 258K 227K 211K 363K 24.97M 370K 2.52M 983K 12.18M 968K 947K 42.25M P/E 2023
-2.12x
P/E 2024 -0.06x
Enterprise Value 845K 1.12M 989K 918K 1.58M 109M 1.61M 10.98M 4.28M 53.1M 4.22M 4.13M 184M EV / Sales 2023
0.84x
EV / Sales 2024 0.21x
Free-Float
24.18%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0.0005
0.02
5 years 0
Extreme 0.0005
0.07
10 years 0
Extreme 0.0005
0.11
Manager TitleAgeSince
Chief Executive Officer 50 2024-06-30
Director TitleAgeSince
Director/Board Member 50 2021-12-12
Chairman 75 2024-04-21
Date Insider Type Main position Quantity % Market Cap.
4/2/24 Buy

Chief Executive Officer

2,808,326 0.6187%
9/8/23 Buy

Chief Executive Officer

400,000 0.0881%
5/24/23 Buy

Chief Executive Officer

500,000 0.1102%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-95.65% 247K
-2.06%-3.53%-7.66%-4.74% 347B
-1.54%-1.89%-9.15%+0.49% 133B
-2.37%-4.83%+0.83%+15.55% 73.32B
+0.33%+2.82%-12.82%-16.98% 52.46B
-1.65%-1.10%-16.55%-22.14% 36.73B
-4.07%-4.43%-11.72%-55.28% 29.9B
-1.24%-2.78%-30.03%-32.34% 19.63B
-2.28%+0.88%+10.79%+6.03% 19.62B
-0.19%-1.80%-3.05%+23.79% 17.91B
Average -1.57%+0.63%-7.94%-18.13% 72.97B
Weighted average by Cap. -1.89%+0.87%-8.06%-5.33%

Financials

2023 2024
Net sales 4.59M 6.11M 5.37M 4.99M 8.61M 592M 8.77M 59.7M 23.29M 289M 22.94M 22.44M 1B 3.97M 5.28M 4.65M 4.32M 7.45M 512M 7.58M 51.62M 20.13M 250M 19.83M 19.4M 866M
Net income -1.69M -2.25M -1.98M -1.84M -3.17M -218M -3.23M -22M -8.58M -106M -8.45M -8.27M -369M -3.06M -4.08M -3.59M -3.33M -5.75M -395M -5.85M -39.84M -15.54M -193M -15.31M -14.98M -668M
Net Debt 287K 382K 336K 312K 538K 36.99M 548K 3.73M 1.46M 18.04M 1.43M 1.4M 62.59M 651K 866K 762K 708K 1.22M 83.9M 1.24M 8.46M 3.3M 40.92M 3.25M 3.18M 142M
Logo Byotrol Limited
Byotrol Plc is a United Kingdom-based specialist infection prevention and control company. The Company operates globally in the animal and human healthcare, industrial, institutional and consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, molds, mycobacteria and algae. Its products can be used stand-alone or as ingredients within existing products, especially in personal hygiene, domestic and industrial disinfection, odor control, food production and food management. The Company sells products based on its anti-microbial technology to professional and consumer end users and retailers (product sales). In the professional sector, it serves human health, animal health and facilities management. In the consumer sector, it serves household, skin care and pet care. It serves customers in the United Kingdom; Europe, Middle East, and Africa (EMEA) and North America and Asia.
Employees
35